Interview with Sean Knox

What is your current role in EPAD? I am the industry co-lead for Work Package 6, together with Jean Georges from Alzheimer Europe. Work Package 6 is the communication and information dissemination engine of EPAD. Our primary purpose is to let the world know what EPAD is doing. Our audience is very broad, ranging from…

Our new sister project AMYPAD officially launches today

Today, our new sister project Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) announces the launch of its novel research initiative, bringing together academic and private research partners to investigate the value of β-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia. Beta-amyloid (β-amyloid) deposition in the brain is…

Sister initiative IMI-Amypad looking for Postdoc

AMYPAD is a European project to establish the true value of amyloid PET in a diagnostic and prognostic setting ( http://www.amypad.eu/). This 5-year project is a collaboration between industry (GEHC, Piramal, Janssen, Ixico) and academic partners funded by the IMI-2 program (total budget 27 million euro). Throughout Europe we will recruit 900 memory clinic patients…

Interview with Shobha Dhadda

What is your current role in EPAD? I am one of the leaders of Work package 2 as well as a steering committee member. Work package 2 is responsible for creation of the disease models and adaptive design platform trial. In addition, I contributed to the development of proof of concept protocol with work package…

Interview with Brian Tom

What is your current role in EPAD? With Adrian Mander, I lead the Disease Modelling Workstream in WP2 (Statistical/Methodology Engine Room). Our principal task is to analyse, on an on-going basis, data arising from the EPAD Longitudinal Cohort Study and the EPAD Proof of Concept Trial in order to refine disease models across the EPAD…

EPAD features prominently at AAIC Conference in Toronto

The Alzheimer’s Association International Conference took place in Toronto from 23 to 28 July. EPAD – funded by the Innovative Medicines Initiative (IMI) – featured in a number of key symposia and communications: At a joint pre-conference meeting of the Global Alzheimer’s Platform and EPAD on global Alzheimer’s research collaboration on 22 July, EPAD researchers…

EPAD recruits its first Spanish research participant

The European Prevention of Alzheimer’s Dementia initiative (EPAD) has recruited its first research participant in Spain, Maria (pictured). The EUR 64 million Europe-wide initiative, which aims to improve our understanding of the early stages of Alzheimer’s disease and how it leads to dementia, is building a registry of 24,000 people and a cohort of 6,000…